Update date
31 Dec 2025
Shareable Research Card
SYRE - Spyre Therapeutics, Inc. Common Stock, Par or Stated Value Per Share
This metric view shows SYRE - Spyre Therapeutics, Inc. common stock, par or stated value per share history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2025
- Latest reported value
- 0.0001
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2025.
- Latest reported value on this page: 0.0001.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Common Stock, Par or Stated Value Per Share
Latest reported common stock, par or stated value per share: 0.0001. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 10 Apr 2026.
Benchmark Context
How Common Stock, Par or Stated Value Per Share compares with peers
Spyre Therapeutics, Inc. is outside the visible top 120 companies for common stock, par or stated value per share in the current sample.
Compared with
Compared with 120 companies reporting common stock, par or stated value per share in USD/shares. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Common Stock, Par or Stated Value Per Share is roughly flat versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Mar 2010 to 22 Feb 2026.
- Nearby companies in this sample: Singularity Future Technology Ltd. and Oaktree Gardens OLP, LLC.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Spyre Therapeutics, Inc.: Common Stock, Par or Stated Value Per Share
Latest period: Q4 2025. Period end: 31 Dec 2025. Units: USD/shares. Frequency: quarterly.
Face amount or stated value per share of common stock.
Metric Snapshot
- Latest value
- 0.0001
- Coverage range
- 31 Dec 2015 - 31 Dec 2025
- Fact rows
- 41
What This Metric Tells You
- Shows the reported level of common stock, par or stated value per share over 31 Dec 2015 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 41 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Common Stock, Par or Stated Value Per Share levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Singularity Future Technology Ltd. (sgly) | 50,000,000 | Instant - 31 Mar 2022 | Open Singularity Future Technology Ltd. Common Stock, Par or Stated Value Per Share |
| 2 | Oaktree Gardens OLP, LLC | 5,115,000 | Instant - 30 Jun 2023 | Open Oaktree Gardens OLP, LLC Common Stock, Par or Stated Value Per Share |
| 3 | ID Auto, Inc. | 1,125,000 | Instant - 31 Oct 2016 | Open ID Auto, Inc. Common Stock, Par or Stated Value Per Share |
| 4 | BRIGHTHOUSE LIFE INSURANCE Co | 25,000 | Instant - 31 Dec 2025 | Open BRIGHTHOUSE LIFE INSURANCE Co Common Stock, Par or Stated Value Per Share |
| 5 | AB Private Credit Investors Corp | 24,000 | Instant - 26 May 2017 | Open AB Private Credit Investors Corp Common Stock, Par or Stated Value Per Share |
| 6 | TOYOTA MOTOR CREDIT CORP | 10,000 | Instant - 31 Mar 2010 | Open TOYOTA MOTOR CREDIT CORP Common Stock, Par or Stated Value Per Share |
Metric Details
- Metric
- Common Stock, Par or Stated Value Per Share (CommonStockParOrStatedValuePerShare)
- Taxonomy
- us-gaap
- Units tracked
- USD/shares
- Frequency coverage
- quarterly
- History range
- 31 Dec 2015 - 31 Dec 2025
- Facts on this page
- 41
- Description
- Face amount or stated value per share of common stock.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Common Stock, Par or Stated Value Per Share, Quarterly (USD/shares)
Common Stock, Par or Stated Value Per Share, YoY Quarterly Change (%)
Spyre Therapeutics, Inc. Quarterly Common Stock, Par or Stated Value Per Share (USD/shares)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.0001 | 0 | 0% | 31 Dec 2025 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2025 | 0.0001 | 0 | 0% | 30 Sep 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q2 2025 | 0.0001 | 0 | 0% | 30 Jun 2025 | 10-Q | 05 Aug 2025 | 2025 | Q2 |
| Q1 2025 | 0.0001 | 0 | 0% | 31 Mar 2025 | 10-Q | 08 May 2025 | 2025 | Q1 |
| Q4 2024 | 0.0001 | 0 | 0% | 31 Dec 2024 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2024 | 0.0001 | 0 | 0% | 30 Sep 2024 | 10-Q/A | 18 Nov 2024 | 2024 | Q3 |
| Q2 2024 | 0.0001 | 0 | 0% | 30 Jun 2024 | 10-Q/A | 18 Nov 2024 | 2024 | Q2 |
| Q1 2024 | 0.0001 | 0 | 0% | 31 Mar 2024 | 10-Q/A | 18 Nov 2024 | 2024 | Q1 |
| Q4 2023 | 0.0001 | 0 | 0% | 31 Dec 2023 | 10-K | 27 Feb 2025 | 2024 | FY |
| Q3 2023 | 0.0001 | 0 | 0% | 30 Sep 2023 | 10-Q | 09 Nov 2023 | 2023 | Q3 |
| Q2 2023 | 0.0001 | 0 | 0% | 30 Jun 2023 | 10-Q | 11 Aug 2023 | 2023 | Q2 |
| Q1 2023 | 0.0001 | 0 | 0% | 31 Mar 2023 | 10-Q | 11 May 2023 | 2023 | Q1 |
| Q4 2022 | 0.0001 | 0 | 0% | 31 Dec 2022 | 10-K/A | 18 Nov 2024 | 2023 | FY |
| Q3 2022 | 0.0001 | 0 | 0% | 30 Sep 2022 | 10-Q | 03 Nov 2022 | 2022 | Q3 |
| Q2 2022 | 0.0001 | 0 | 0% | 30 Jun 2022 | 10-Q | 04 Aug 2022 | 2022 | Q2 |
| Q1 2022 | 0.0001 | 0 | 0% | 31 Mar 2022 | 10-Q | 05 May 2022 | 2022 | Q1 |
| Q4 2021 | 0.0001 | 0 | 0% | 31 Dec 2021 | 10-K | 02 Mar 2023 | 2022 | FY |
| Q3 2021 | 0.0001 | 0 | 0% | 30 Sep 2021 | 10-Q | 04 Nov 2021 | 2021 | Q3 |
| Q2 2021 | 0.0001 | 0 | 0% | 30 Jun 2021 | 10-Q | 05 Aug 2021 | 2021 | Q2 |
| Q1 2021 | 0.0001 | 0 | 0% | 31 Mar 2021 | 10-Q | 10 May 2021 | 2021 | Q1 |
| Q4 2020 | 0.0001 | 0 | 0% | 31 Dec 2020 | 10-K | 08 Mar 2022 | 2021 | FY |
| Q3 2020 | 0.0001 | 0 | 0% | 30 Sep 2020 | 10-Q | 05 Nov 2020 | 2020 | Q3 |
| Q2 2020 | 0.0001 | 0 | 0% | 30 Jun 2020 | 10-Q | 10 Aug 2020 | 2020 | Q2 |
| Q1 2020 | 0.0001 | 0 | 0% | 31 Mar 2020 | 10-Q | 07 May 2020 | 2020 | Q1 |
| Q4 2019 | 0.0001 | 0 | 0% | 31 Dec 2019 | 10-K | 18 Mar 2021 | 2020 | FY |
| Q3 2019 | 0.0001 | 0 | 0% | 30 Sep 2019 | 10-Q | 06 Nov 2019 | 2019 | Q3 |
| Q2 2019 | 0.0001 | 0 | 0% | 30 Jun 2019 | 10-Q | 06 Aug 2019 | 2019 | Q2 |
| Q1 2019 | 0.0001 | 0 | 0% | 31 Mar 2019 | 10-Q | 07 May 2019 | 2019 | Q1 |
| Q4 2018 | 0.0001 | 0 | 0% | 31 Dec 2018 | 10-K | 24 Feb 2020 | 2019 | FY |
| Q3 2018 | 0.0001 | 0 | 0% | 30 Sep 2018 | 10-Q | 08 Nov 2018 | 2018 | Q3 |
| Q2 2018 | 0.0001 | 0 | 0% | 30 Jun 2018 | 10-Q | 09 Aug 2018 | 2018 | Q2 |
| Q1 2018 | 0.0001 | 0 | 0% | 31 Mar 2018 | 10-Q | 08 May 2018 | 2018 | Q1 |
| Q4 2017 | 0.0001 | 0 | 0% | 31 Dec 2017 | 10-K | 07 Mar 2019 | 2018 | FY |
| Q3 2017 | 0.0001 | 0 | 0% | 30 Sep 2017 | 10-Q | 07 Nov 2017 | 2017 | Q3 |
| Q2 2017 | 0.0001 | 0 | 0% | 30 Jun 2017 | 10-Q | 09 Aug 2017 | 2017 | Q2 |
| Q1 2017 | 0.0001 | 0 | 0% | 31 Mar 2017 | 10-Q | 09 May 2017 | 2017 | Q1 |
| Q4 2016 | 0.0001 | 0 | 0% | 31 Dec 2016 | 10-K | 13 Mar 2018 | 2017 | FY |
| Q3 2016 | 0.0001 | 30 Sep 2016 | 10-Q | 09 Nov 2016 | 2016 | Q3 | ||
| Q2 2016 | 0.0001 | 30 Jun 2016 | 10-Q | 09 Aug 2016 | 2016 | Q2 | ||
| Q1 2016 | 0.0001 | 31 Mar 2016 | 10-Q | 19 May 2016 | 2016 | Q1 | ||
| Q4 2015 | 0.0001 | 31 Dec 2015 | 10-K | 23 Mar 2017 | 2016 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.